EUVIMEDEUVIMED entdecken
Übersichtsarbeit

High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?

Neha Wadhavkar iD, Laura Varnum, Steven F Moss

Basic & Clinical Pharmacology & Toxicology · 2025-07 · 137 (1)

DOI: 10.1111/bcpt.70070 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 13.06.2025. Verfasst von Neha Wadhavkar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Brown University, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Sucralfate, Anti-Ulcer Agents, Gastrointestinal Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sucralfate is a commonly prescribed medication in use for decades. Despite the availability of more effective medications for acid‐dyspeptic conditions, including proton pump inhibitors and histamine H2‐receptor antagonists, sucralfate continues to be utilized for upper gastrointestinal symptoms. We reviewed the limited evidence base supporting the approval and ongoing usage of sucralfate and performed a cost analysis using the ClinCalc database. The financial impact of sucralfate was comparable to famotidine, lansoprazole and ranitidine. We encourage further studies to accurately gauge the true clinical efficacy of sucralfate and to question its ongoing prescription until then.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SucralfateAnti-Ulcer AgentsGastrointestinal DiseasesHumansProton Pump InhibitorsHistamine H2 AntagonistsDrug CostsCost-Benefit Analysis

Stichwörter der Autor:innen

GERDclinical pharmacologyfunctional dyspepsiahealth economicspeptic ulcer disease

Substanzen

SucralfateAnti-Ulcer AgentsProton Pump InhibitorsHistamine H2 Antagonists

Autor:innen und Institutionen

  • Department of Internal Medicine, Brown University, Providence, Rhode Island, USA.
  • UMass Memorial Specialty Pharmacy, UMass Memorial Medical Center, Worcester, Massachusetts, USA.
  • Division of Gastroenterology, Brown University, Providence, Rhode Island, USA.

ORCID-Profile: Neha Wadhavkar

Zitieren

APA

Wadhavkar, N., Varnum, L., & Moss, S. F. (2025). High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?. Basic & Clinical Pharmacology & Toxicology, 137(1). https://doi.org/10.1111/bcpt.70070

Vancouver

Wadhavkar N, Varnum L, Moss SF. High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?. Basic & Clinical Pharmacology & Toxicology. 2025;137(1). doi:10.1111/bcpt.70070

BibTeX
@article{Wadhavkar2025,
  author = {Wadhavkar, Neha and Varnum, Laura and Moss, Steven F},
  title = {High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  volume = {137},
  number = {1},
  doi = {10.1111/bcpt.70070}
}
Kostenlos starten →